Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events
- 30 June 2006
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 151 (6), 1187-1193
- https://doi.org/10.1016/j.ahj.2005.06.026
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Oral Anticoagulants vs Aspirin in Nonvalvular Atrial FibrillationJama-Journal Of The American Medical Association, 2002
- ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summaryJournal of the American College of Cardiology, 2001
- Cardioembolic vs. Noncardioembolic Strokes in Atrial Fibrillation: Frequency and Effect of Antithrombotic Agents in the Stroke Prevention in Atrial Fibrillation StudiesCerebrovascular Diseases, 2000
- Antithrombotic Therapy To Prevent Stroke in Patients with Atrial FibrillationAnnals of Internal Medicine, 1999
- An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1996
- Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial FibrillationArchives of Internal Medicine, 1994
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- Prevalence of Cardiovascular Disease and Diabetes Mellitus in Residents of Rochester, MinnesotaMayo Clinic Proceedings, 1990
- Atrial Fibrillation: A Major Contributor to Stroke in the ElderlyArchives of Internal Medicine, 1987